ClinicalTrials.gg
RecruitingNCT06420830Updated Nov 4, 2026

Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.

An observational study in Aortic Valve Stenosis and Transcatheter Aortic Valve Replacement, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 4, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.

Planned enrollment
21st of 27
150 · median 320
Started
2024
with 2 others
Observational
27 of 87
8 open now
Primary completion
2027-10
later than 23 of 35 live
Registered
81st of 87
by date
Lead sponsor
5 of 87
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 21st largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2024, is one of 27 observational ones, reaches primary completion later than 23 of the 35 other live ones, and was the 81st registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Aortic Valve Stenosis with a site in Canada, or all of them as a file.
02

Study summary

The issue of valve durability has become one of the most important aspects in the TAVR field in recent years since transcatheter aortic valve replacement has been progressively applied to younger patients with a low co-morbidity burden. The SAPIEN 3 Ultra RESILIA valve represents the last generation of the SAPIEN valve system and includes several important iterations (newer leaflet calcium-blocking technology targeting calcium-attracting free aldehydes, dry tissue storage, newer skirt textile design) that should translate into a favorable impact on valve durability at mid- to long- term follow-up

Read the detailed description

Prospective observational registry including patients with severe aortic stenosis undergoing TAVR with the SAPIEN 3 Ultra RESILIA valve. All patients who will survive the procedure will undergo a clinical and echocardiographic follow-up at 1-3 months (± 15 days), at 1-year (±30 days), 3-5 year (±30 days), 6-8 year (±30 days) and 9-10 year (±30 days) after valve implantation. Transthoracic echocardiography (TTE) exams (baseline, 1-3-month, 1 year, 3-5 years, 6-8 years, and 9-10 years post-procedure) will be evaluated in a Centralized Echocardiographic Core Lab at the Quebec Heart and Lung Institute. The measurements obtained in the Core Lab regarding transvalvular gradient, EOA, PPM and PVL at 1-3 months will determine the primary outcome of the study.

03

Conditions studied

  • Aortic Valve Stenosis
  • Transcatheter Aortic Valve Replacement
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Population Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 Ultra RESILIA valve.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion criteria - Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.
  • Successful valve implantation of the SAPIEN 3 Ultra RESILIA valve.

VARC-3- defined technical success defined as:

  • Freedom from mortality
  • Successful access, delivery of the device, and retrieval of the delivery system
  • Correct positioning of a single prosthetic heart valve into the proper anatomical location
  • Freedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access related, or cardiac structural complication - Absence of severe procedural or in-hospital complications (VARC-3 definitions): mortality, stroke, bleeding type 2-4, myocardial infarction, need for a second valve, valve embolization, coronary obstruction, annular rupture.

Exclusion criteria

Exclusion Criteria:

  • Age >80 years
  • Severe pulmonary disease ( \<50% predicted or need for home oxygen)
  • Severe renal dysfunction ( \<30 ml/min/1.73m2)
  • Frailty (Clinical Frailty Scale > 4)
  • Severe coronary disease (SYNTAX score >32)
  • ≤30%
  • Moderate-to-severe mitral regurgitation
  • Severe tricuspid regurgitation
  • Pulmonary systolic pressure >60 mmHg
  • STS-PROM >5%
  • Any disease leading to a \<5 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • ProcedureSAPIEN 3 Ultra RESILIA Valve

    Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.

06

What researchers measure

Primary outcomes

  1. Transvalvular gradient

    Residual (peak and mean) transvalvular gradient

    Time frame: 1-3 months

  2. Effective orifice area (EOA)

    EOA evaluated by echocardiography imaging

    Time frame: 1-3 months

  3. Prosthesis-patient mismatch

    Moderate or severe prothesis-patient mismatch (defines as an index aortic valve area 0.85-0.66 cm2/m2 (moderate), ≤0.65 cm2/m2 (severe) for patient with BMI ˂30km/m2 and 0.70-0.56 cm2/m2 (moderate), ≤0.55 cm2/m2 (severe) for patient with BMI ≥30km/m2 and/or moderate-severe aortic regurgitation (AR) (VARC-3 definition).

    Time frame: 1-3 months

  4. Paravalvular leaks

    Paravalvular leaks evaluated by echocardiography imaging

    Time frame: 1-3 months

Secondary outcomes

  1. Transvalvular gradient

    Residual (maximal and mean) transvalvular gradient

    Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.

  2. Effective orifice area (EOA)

    EOA evaluated by echocardiography imaging

    Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.

  3. Bioprosthetic valve dysfunction

    Bioprosthetic valve dysfunction evaluated by VARC3 criteria

    Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.

  4. Paravalvular leaks

    Paravalvular leaks evaluated by echocardiography imaging

    Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.

  5. Bioprosthetic valve dysfunction

    Incidence rate (per 100 patient-years) of bioprosthetic valve dysfunction (stage 2 or 3)

    Time frame: yearly

  6. Bioprosthetic valve failure

    Incidence rate (per 100 patient-years) of bioprosthetic valve failure

    Time frame: yearly

  7. Bioprosthetic valve failure

    Bioprosthetic valve failure evaluated by VARC3 criteria

    Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.

  8. Clinical events

    Individual: mortality, stroke, bleeding type 2-4, cardiac rehospitalization, heart failure rehospitalization

    Time frame: 1month and yearly up to 10-year

  9. Valve thrombosis

    Number of patients with valve thrombosis

    Time frame: 1-3 months and yearly up to 10-year

  10. Valve endocarditis

    Number of patients with valve endocarditis

    Time frame: 1-3 months and yearly up to 10-year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Writing Committee Members; Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C; ACC/AHA Joint Committee Members; O'Gara PT, Beckman JA, Levine GN, Al-Khatib SM, Armbruster A, Birtcher KK, Ciggaroa J, Deswal A, Dixon DL, Fleisher LA, de las Fuentes L, Gentile F, Goldberger ZD, Gorenek B, Haynes N, Hernandez AF, Hlatky MA, Joglar JA, Jones WS, Marine JE, Mark D, Palaniappan L, Piano MR, Spatz ES, Tamis-Holland J, Wijeysundera DN, Woo YJ. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2021 Aug;162(2):e183-e353. doi: 10.1016/j.jtcvs.2021.04.002. Epub 2021 May 8. No abstract available. PubMed 33972115 ↗
  • Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Juni P, Pierard L, Prendergast BD, Sadaba JR, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395. No abstract available. PubMed 34453165 ↗
  • Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1695-1705. doi: 10.1056/NEJMoa1814052. Epub 2019 Mar 16. PubMed 30883058 ↗
  • Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16. PubMed 30883053 ↗
  • Montarello NJ, Willemen Y, Tirado-Conte G, Travieso A, Bieliauskas G, Sondergaard L, De Backer O. Transcatheter aortic valve durability: a contemporary clinical review. Front Cardiovasc Med. 2023 May 9;10:1195397. doi: 10.3389/fcvm.2023.1195397. eCollection 2023. PubMed 37229228 ↗
  • Ferreira-Neto AN, Rodriguez-Gabella T, Guimaraes L, Freitas-Ferraz A, Bernier M, Figueiredo Guimaraes C, Pasian S, Paradis JM, Delarochelliere R, Dumont E, Mohammadi S, Kalavrouziotis D, Cote M, Pibarot P, Rodes-Cabau J. Multimodality evaluation of transcatheter structural valve degeneration at long-term follow-up. Rev Esp Cardiol (Engl Ed). 2021 Mar;74(3):247-256. doi: 10.1016/j.rec.2020.02.002. Epub 2020 Apr 8. English, Spanish. PubMed 32278660 ↗
  • Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22. PubMed 20961243 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2027, 40 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 40 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Oct 2027, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 20, 2024
StartActual
May 16, 2024
Primary completionEst.
Oct 1, 2027was Oct 2026
CompletionEst.
Sep 1, 2034
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Oct 1, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Oct 1, 2026→Oct 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06420830
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Josep Rodes-Cabau (Principal Investigator, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval) — Principal investigator
First posted
May 20, 2024
Start date
May 16, 2024
Primary completion
Oct 1, 2027 (estimated)
Completion
Sep 1, 2034 (estimated)
Last update
Nov 4, 2026

Study contacts

Josep Rodés-Cabau, MD
Contact
josep.rodes@criucpq.ulaval.ca
4186568711
Emilie Pelletier beaumont, MSc
Contact
emilie.pelletier-beaumont@criucpq.ulaval.ca
418-656-8711 ext. 3929
Josep Rodés-Cabau, MD
principal investigator · IUCPQ-UL
Emilie Pelletier beaumont, MSc
study director · Fondation IUCPQ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion